Quest's Goal of Shifting Some MDx Testing to Hospital Labs Gains Momentum

The bump came after EU regulators cleared two new Simplexa molecular assays developed by its Focus business. The tests, for Epstein-Barr and BK viruses, can be sold in 35 European countries, a huge, untapped market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.